- Case report
- Open Access
Living donor liver transplantation for idiopathic portal hypertension with extrahepatic portal vein stenosis and splenic artery aneurysms: a case report and review of the literature
BMC Surgery volume 20, Article number: 257 (2020)
Idiopathic portal hypertension (IPH) generally has a good prognosis and rarely results in liver transplantation. Furthermore, there are few reports of living donor liver transplantation (LDLT) for IPH with extrahepatic portal vein stenosis.
We report the case of a 51-year-old female patient diagnosed with IPH more than 20 years ago. She suffered severe jaundice, massive ascites, and encephalopathy at the time of her visit to our hospital. The patient’s extrahepatic portal vein showed a scar-like stenosis, and the portal flow was completely hepatofugal. Collateral circulation such as the splenorenal shunt was well developed, and multiple splenic artery aneurysms up to 2 cm were observed in the splenic hilum. Her Model for End-Stage Liver Disease score increased to over 40 because of renal dysfunction, requiring temporary dialysis. We performed LDLT using her husband’s right lobe graft and splenectomy. The extrahepatic stenotic portal vein was completely resected, and the superficial femoral vein (SFV) graft collected from the recipient’s right leg was used for portal reconstruction as an interposition graft. Although the clinical course after LDLT had many complications, the patient was discharged on postoperative day 113 and has been fine for 2 years after LDLT. Histopathologically, the explanted liver had obliterative portal venopathy, nodular regenerative hyperplasia, and incomplete septal cirrhosis.
This case showed that severe IPH is occasionally associated with extrahepatic portal vein stenosis and can be treated with LDLT with portal vein reconstruction using an interposition graft. It was also suggested that the SFV is a useful choice for the interposition graft.
Idiopathic portal hypertension (IPH) comprises disorders that develop increased portal pressure in the absence of cirrhosis . The etiology of IPH is pooly understood as the site of resistance to portal flow is at the presinusoidal level without cirrhosis . Many terms have been used for this disease such as non-cirrhotic portal fibrosis, nodular regenerative hyperplasia (NRH), hepatoportal sclerosis, and idiopathic noncirrhotic portal hypertension; IPH has been the most commonly used term in Japan.
Although most IPH patients have a good prognosis with the treatment for esophageal varices and/or other complications due to portal hypertension, some develop end-stage liver failure and need for liver transplantation [3,4,5]. It has been reported that about 6% of patients with IPH required liver transplantation . In Japan, there were 8795 living liver transplants until 2017, of which 10 were for IPH patients, including 9 adults and 1 child . Living donor liver transplantation (LDLT) for IPH accounts for about 0.1% of the total, which is an indication of its rarity.
Since IPH is considered to have portal hypertension at the presinusoidal level, there are few reports of LDLT for IPH with extrahepatic portal vein stenosis. Although it is unclear when and how the extrahepatic portal vein stenosis was completed in IPH, this situation required complicated portal vein reconstruction with interposition vein graft, jumping vein graft , or renoportal anastomosis  using autologous vein graft.
The superficial femoral vein (SFV) seems to be the preferred option for vein grafts because of its caliber, wall thickness, and length obtained. An approximately 15–20 cm segment of the right-side SFV could be usually obtained from the recipient. The collection procedure is technically simple, and postoperative complications such as lower extremity temporary edema are usually not severe, with no permanent complications .
Splenic artery aneurysms (SAAs), occurring in 7% to 17% of patients with cirrhosis, often result in catastrophic rupture after liver transplantation . SAAs are closely related to severe portal hypertension with large portosystemic collaterals. While visceral aneurysms larger than 2 cm are more likely to rupture, preventive treatment should be encouraged regardless of the size of SAAs, because the risk of rupture increases during the perioperative period of liver transplantation, in which hemodynamic and proteolytic changes occur [11, 12]. Whether to select interventional radiology (IVR) or surgical treatment such as splenectomy as a treatment method needs to be individually selected according to the patient’s general condition, and the location and number of SAAs.
We report a very rare case of end-stage IPH with extrahepatic portal vein stenosis and SAAs close to the hilum of the spleen. As the patient was so sick that she had to temporarily undergo dialysis, she could not get any preventive treatment against the SAAs before liver transplantation. We decided to perform LDLT and splenectomy with a complicated portal vein reconstruction using the SFV graft.
A 51-year-old female patient was admitted to explore the possibility of liver transplantation for liver failure due to IPH. She had NRH on liver biopsy 20 years ago and was diagnosed with IPH. The patient’s extrahepatic portal vein showed a scar-like stenosis, and the portal flow was completely hepatofugal. Collateral circulation such as the splenorenal shunt was well developed, and dense calcification was observed at the site of splenomesenteric junction (Fig. 1), suggesting that the usual portal reconstruction would be impossible. Furthermore, multiple splenic artery aneurysms (SAAs) up to 2 cm were observed in the splenic hilum (Fig. 2). The patient’s condition was getting worse and her Child–Pugh score became 13, and her Model for End-Stage Liver Disease (MELD) score increased to over 40 because of renal dysfunction, requiring temporary dialysis. Due to the high risk of rupture during the perioperative period of liver transplantation, it was considered necessary to take some preventive measures against the SAAs; however, it was difficult to perform preoperatively due to her medical condition. Therefore, splenectomy at the time of transplantation was needed. Since the splenorenal shunt was likely to be destroyed during splenectomy, portal vein reconstruction using renoportal anastomosis was considered to not be possible. For the jumping vein graft, long-term patency was a concern because it passed through a non-physiological route. We decided to use an interposition autologous graft between the splenomesenteric junction and the graft portal vein stump.
LDLT using her husband’s right lobe graft was performed. The graft recipient weight ratio (GRWR) of the graft was 1.26, which was rated as a sufficient large for the recipient. After total hepatectomy, the recipient’s right side SFV graft was harvested. The portal vein was dissected to the side of the pancreas, and the dorsal side of the pancreas was tunneled to confirm the splenic vein (SPV) and superior mesenteric vein (SMV). After clamping the SMV and SPV, the stenotic portal vein was completely resected, and the dense calcification of vascular endothelium was removed at the splenomesenteric junction. The SFV graft was anastomosed to the splenomesenteric junction in an end-to-side fashion. After right hepatic vein reconstruction and confirming the sufficient front flow of the portal vein, an end-to-end anastomosis was performed on the portal vein of the graft liver and the SFV graft (Fig. 3).
The clinical course after transplantation had many complications. An intraabdominal abscess due to grade B pancreatic fistula classified by international study group of pancreatic fistula (ISGPF)  after splenectomy for splenic artery aneurysm occurred on postoperative day (POD) 14. It was gradually relieved by percutaneous CT guide drainage. Late onset bile leakage occurred on POD 32, which was managed by drainage and biliary stent. A large amount of ascites appeared and the anastomotic stenosis between the SFV graft and the splenomesenteric junction was found on POD 52. A small laparotomy was performed to secure the ileocolic vein, and balloon dilatation (diameter of 8 mm) of anastomotic stenosis was achieved by interventional radiology technique via the ileocolic venous approach. The pressure difference before and after the anastomosis site was 15 mmHg before balloon dilatation, and 3 mmHg after the treatment. Massive ascites had been gradually improved and the patient was discharged on POD 113. The explant liver histologically showed obstructive portal venopathy, NRH, and incomplete septal cirrhosis, which was typical of IPH (Fig. 4).
The clinical course after discharge was uneventful and the SFV graft patency was excellent at 2 years after LDLT (Fig. 5).
Discussion and conclusion
IPH is a rare disease characterized by portal hypertension without cirrhosis. The prognosis of IPH is considered as feasible with management for esophageal varices and/or splenomegaly by supportive treatments such as endoscopic, radiological, and surgical approach. The definite etiology of IPH is still uncertain, however, there are several theories that have been attributed to the potential pathogenesis of IPH. The contributing factors include immunological disorders, infections, and genetic variations .
IPH rarely results in neither end-stage liver failure nor requiring liver transplantation. Past case reports for severe IPH requiring liver transplantation were summarized in Table 1 [3, 5, 9, 14,15,16,17,18,19,20]. To date, about 50 cases of liver transplantation have been reported for IPH. Approximately 80% of the reported cases were male, and few patients had been diagnosed with IPH preoperatively. Most of cases were cadaveric liver transplantation cases for cryptogenic cirrhosis, and reports of LDLT cases were even rarer, and were limited to reports from India and Japan. Out of 8795 LDLT in Japan up to 2017, only 10 (0.1%) cases for IPH. The same pathological condition as IPH is called for Non-cirrhotic portal fibrosis (NCPF) in India. Saigal et al. reported that 10 (2.5%) out of 406 LDLT cases were pathologically diagnosed as pure NCPF from the study of explant livers in India. This rate was extremely high as compared to that in Japan, however, whether or not the IPH in Japan was the same condition as NCPF in India may need further verification.
When the disease duration of IPH had been long, the extrahepatic portal vein itself may occasionally become atrophic and scar-like because of the hepatofugal portal flow and/or unknown reasons. These situations may result in stenosis of the extrahepatic portal vein. To date, there is only one case report of liver transplantation for IPH with extrahepatic portal vein stenosis. In that case, a right lobe LDLT with renoportal anastomosis was performed using the recipient’s internal jugular vein graft for portal reconstruction . However, in our case, splenectomy for splenic artery aneurysms might destroy a part of the splenorenal shunt, suggesting that renoportal anastomosis might be impossible. Alternatively, portal vein reconstruction with interposition vein graft between the splenomesenteric junction and donor portal vein stump was performed using a recipient’s superficial femoral vein (SFV).
The SFV graft obtained from the recipient is not only an autologous vein graft with no immune reaction, but also a very long vein graft with a sufficient diameter. A 15–20 cm length graft can be usually obtained, so the SFV graft alone can cover all the vein graft reconstruction in LDLT [8, 21]. The procurement procedure is simple, but the length of the skin incision may be longer than that of other vein grafts. Since SFV grafts have valves in their lumens, we have dissected all these valves under the direct vision. It is well known that harvesting the SFV peripherally to the profound femoral vein inflow is well tolerated and associated with only minimal lower extremity venous morbidity . The lower extremity suffered edema, but it improved within about 1 month, and did not pose long-term problem.
In our case, anastomotic stenosis between the splenomesenteric junction and SFV graft occurred on POD 52, resulting in increasing ascites. Conservative treatments such as the use of diuretics did not succeed; the re-operation and balloon dilatation of the anastomotic stenosis were performed using the interventional radiology technique via the ileocolic vein. Possible reasons of anastomotic stenosis might include technical errors, and/or a twisting associated with the graft regeneration, but it is not clear. Despite the reason being unclear, a single attempt of balloon dilatation had completely solved the problem, therefore, we determined that this complication should not raise doubts about the usefulness of the SFV graft in portal reconstruction.
The diagnosis of IPH is extremely difficult because the liver is usually atrophic and closely resembles cirrhosis in both clinical symptoms and diagnositic imaging in the late stage of IPH. Therefore, only histological findings obtained by liver biopsy will lead to the precise diagnosis of IPH preoperatively. Histopathologically, almost all patients with IPH have some degree of obliterative portal venopaty, furthermore, NRH and incomplete septal cirrhosis are also characteristic findings of IPH. Our patient had an NRH on liver biopsy and was diagnosed with IPH 20 years before the first visit to our hospital. The patient’s explanted liver showed evidence of obliterative portal venopathy, NRH, and incomplete septal cirrhosis, which were compatible with IPH, but not with end-stage cirrhosis.
In conclusion, we reported a very rare case of end-stage IPH with extrahepatic portal vein stenosis and the SAAs close to the hilum of the spleen. This case showed that severe IPH is occasionally associated with extrahepatic portal vein stenosis and can be treated with LDLT with portal vein reconstruction using an interposition graft. It was also suggested that the SFV is a useful choice for the interposition graft.
Idiopathic portal hypertension
Nodular regenerative hyperplasia
Living donor liver transplantation
Superficial femoral vein
Splenic artery aneurysm
Superior mesenteric vein
Non-cirrhotic portal fibrosis
Tanaka T, Sugawara Y, Kokudo N. The current clinical aspects of idiopathic portal hypertension. Intractable Rare Dis Res. 2013;2:94–7.
Khanna R, Sarin SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction. Hepatol Int. 2018;12:S148–67.
Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transplant. 2005;11:627–34.
Meijer B, Simsek M, Blokzijl H, Man RA, Coenraad MJ, Dijkstra G, et al. Nodular regenerative hyperplasia rarely leads to liver transplantation: a 20-year cohort study in all Dutch liver transplant units. United Eur Gastroenterol J. 2017;5:658–67.
Inokuma T, Eguchi S, Tomonaga T, Miyazaki K, Hamasaki K, Tokai H, et al. Acute Deterioration of idiopathic portal hypertension requiring living donor liver transplantation: a case report. Dig Dis Sci. 2009;54:1597–601.
Schouten JNL, Nevens F, Hansen B, Laleman W, van den Born M, Komuta M, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther. 2012;35:1424–33.
The Japanese liver transplantation society. Liver transplantation in Japan-Registry by the Japanese liver transplantation society. Ishoku. 2019;53:109–23.
Sato K, Sekiguchi S, Watanabe T, Enomoto Y, Akamastu Y, Kawagishi N, et al. The use of recipient superficial femoral vein as a venous graft for portal vein reconstruction in right lobe living donor liver transplantation. Transplant Proc. 2009;41:195–7.
Matsumoto Y, Ikegami T, Morita K, Yoshizumi T, Kayashima H, Shirabe K, et al. Renoportal anastomosis in right lobe living donor liver transplantation: report of a case. Surg Today. 2013;43:1316–20.
Wells JK, Hagino RT, Bargmann KM, Jackson MR, Valentine RJ, Kakish HB, et al. Venous morbidity after superficial femoral-popliteal vein harvest. J Vasc Surg. 1999;29:282–9.
Moon DB, Lee SG, Hwang S, Kim KH, Ahn CS, Ha TY, et al. Characteristics and management of splenic artery aneurysms in adult living donor liver transplant recipients. Liver Transplant. 2009;15:1535–41.
Asthana S, Toso C, McCarthy M, Shapiro AMJ. The management of splenic artery aneurysm in patients awaiting liver transplantation. Clin Transplant. 2010;24:691–4.
Bassi C, Marchegiani G, Dervenis C, Sarr M, Hilal MA, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2016;161:584–91.
McDonald JA, Painter DM, Gallagher ND, McCaughan GW. Nodular regenerative hyperplasia mimicking cirrhosis of the liver. Gut. 1990;31:725–7.
Elariny HA, Mizrahi SS, Hayes DH, Boudreaux JP, Hussey JL, Farr GH Jr. Nodular regenerative hyperplasia: a controversial indication for orthotopic liver transplantation. Transplant Int. 1994;7:309–13.
Bernard PH, Le Bail B, Cransac M, Barcina MG, Caries J, Balabaud C, et al. Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation. J Hepatol. 1995;22:495–9.
Loinaz C, Colina F, Musella M, Lopez-Rios F, Gomez R, Jimenez C, et al. Orthotopic liver transplantation in 4 patients with portal hypertension and non-cirrhotic nodular liver. Hepatogastroenterology. 1998;45:1787–94.
Radomski JS, Chojnacki KA, Moritz MJ, Rubin R, Armenti VT, Wilson GA, et al. Results of liver transplantation for nodular regenerative hyperplasia. Am Surg. 2000;66:1067–70.
Dumortier J, Bizollon T, Scoazec JY, Chevallier M, Bancel B, Berger F, et al. Orthotopic liver transplantation for idiopathic portal hypertension: indication and outcome. Scand J Gastroenterol. 2001;36:417–22.
Saigal S, Nayak NC, Jain D, Kumaran V, Mohanka R, Saraf N, et al. Non-cirrhotic portal fibrosis related end stage liver disease in adults: evaluation from a study on living donor liver transplant recipients. Hepatol Int. 2011;5:882–9.
Kornberg A, Heyne J, Schotte U, Hommann M, Scheele J. Hepatic venous outflow reconstruction in right lobe living-donor liver graft using recipient’s superficial femoral vein. Am J Transplant. 2003;3:1444–7.
We would like to thank Editage (www.editage.com) for English language editing.
No funding was received for this study.
Ethics approval and consent to participate
The patient has signed an informed consent. This study in terms of various vein reconstruction methods in liver transplantation was approved by the local institutional review board of the Tokyo Medical University (T2019-0088).
Consent for publication
A written consent for publication was obtained from the patient for the publication of all potentially identifiable clinical data and accompanying images. A copy of this consent form is available for review by the editor of this journal.
Availability of data and materials
The clinical datasets supporting the conclusions of this study were derived from the patient electronic files. Therefore, restrictions to availability apply due to data protection regulations. Anonymized data are, however, available from the corresponding author on reasonable request and with permission of the Tokyo Medical University Hachioji Medical Center and the local review board.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kawachi, S., Chiba, N., Nakagawa, M. et al. Living donor liver transplantation for idiopathic portal hypertension with extrahepatic portal vein stenosis and splenic artery aneurysms: a case report and review of the literature. BMC Surg 20, 257 (2020). https://doi.org/10.1186/s12893-020-00921-6
- Idiopathic portal hypertension
- Extrahepatic portal vein stenosis
- Living donor liver transplantation
- Splenic artery aneurysms
- Superficial femoral vein graft